drugset
drugset / Trial / NCT02008279

A Safety and Pharmacokinetics Study of CNTO 3157 in Healthy Japanese and Caucasian Participants

NCT02008279 ↗

Phase 1 Completed 40 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to find out if different doses of CNTO 3157 are well tolerated in both Japanese and Caucasian men as well as to understand how the body absorbs and removes the study drug after being injected or infused into the body.

Timeline

Start
2013-12
Primary completion
2014-08
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Subject CNTO 3157 Monoclonal antibody 100 mg Subcutaneous
Subject CNTO 3157 Monoclonal antibody 300 mg Subcutaneous
Subject CNTO 3157 Monoclonal antibody 600 mg Subcutaneous

Indications

No indication recorded.